

# **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

## **BioStem Technologies, Inc.**

2836 Center Port Circle, Pompano Beach, FL 33064

---

(954)-380-8342

www.biostemtech.com

info@biostemtech.com

SIC Code: 2836

## **Quarterly Report**

**For the period ending June 30, 2024 (the "Reporting Period")**

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

16,287,139 as of June 30, 2024. *(Current Reporting Period Date or More Recent Date)*

16,343,762 as of March 31, 2024. *(Previous Reporting Period Date or More Recent Date)*

16,214,390 as of December 31, 2023. *(Most Recent Completed Fiscal Year End)*

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes: ☐ No: ☒

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

- a. BioStem Technologies, Inc. (Active)
- b. BioStem Technologies was formerly named Caribbean International Holdings, Inc., until August 28, 2014, when the issuer changed its name to BioStem Technologies, Inc.
- c. Caribbean International Holdings, Inc. was formerly named Caribbean Casino & Gaming Corporation, until November 29, 2012, when it changed its name to Caribbean International Holdings, Inc.
- d. Caribbean Casino & Gaming Corporation was formed on February 12, 2009.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g., active, default, inactive):

Florida; Active Status.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

The address(es) of the issuer's principal executive office:

2836 Center Port Circle, Pompano Beach, FL 33064

The address(es) of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

## 2) Security Information

### **Transfer Agent**

Name: V Stock Transfer  
Phone: 212-828-8436  
Email: info@vstocktransfer.com  
Address: 18 Lafayette Pl, Woodmere, NY 11598

### **Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	<u>BSEM</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>090684200</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	975,000,000	<u>as of date: June 30, 2024</u>
Total shares outstanding:	16,287,139	<u>as of date: June 30, 2024</u>
Total number of shareholders of record:	3,151	<u>as of date: June 30, 2024</u>

*All additional class(es) of publicly quoted or traded securities (if any):*

NA

### **Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	Series A-1 Preferred Stock	
CUSIP (if applicable):	NA	
Par or stated value:	No Par	
Total shares authorized:	300	<u>as of date: June 30, 2024</u>
Total shares outstanding (if applicable):	300	<u>as of date: June 30, 2024</u>
Total number of shareholders of record (if applicable):	3	<u>as of date: June 30, 2024</u>

Exact title and class of the security:	Series B-1 Preferred Stock	
CUSIP (if applicable):	NA	
Par or stated value:	No Par Value	
Total shares authorized:	500,000	<u>as of date: June 30, 2024</u>
Total shares outstanding (if applicable):	5	<u>as of date: June 30, 2024</u>
Total number of shareholders of record (if applicable):	1	<u>as of date: June 30, 2024</u>

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

**1. For common equity, describe any dividend, voting and preemption rights.**

Each holder is entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders of the Company. Holders of Common Stock are not entitled to any preemptive rights.

**2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

**Series A-1 Convertible Preferred Shares:**

The Company has designated 300 shares of preferred stock as "Series A-1 Convertible Preferred Shares". The Series A-1 Convertible Preferred Shares entitled their holders to a number of votes equal to the number of shares issuable upon conversion times 2,000,000 granting the holders of Series A-1 Convertible Preferred Shares, as a group, effective control of the Company.

Series A-1 Convertible Preferred Shares are convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but not in part, into 300 shares of common stock.

Holders of Series A-1 Convertible Preferred Shares are not entitled to receive dividends out of assets legally available thereof, prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation.

**Series B-1 Convertible Preferred Shares:**

The Company has designated 500,000 shares of preferred stock as "Series B-1 Convertible Preferred Shares".

The Series B-1 Convertible Preferred Shares entitle their holders to votes equal to the number of shares issuable upon conversion.

Each Series B-1 Convertible Preferred Share is convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but not in part, into six (6) shares of common stock.

The Series B-1 Preferred Shares shall be entitled to receive an annual dividend, payable in newly issued common stock, in an amount equal to ten percent (10%) of the number of then existing Series B-1 Preferred Shares issued and outstanding prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation. This Dividend shall be cumulative.

**3. Describe any other material rights of common or preferred stockholders.**

None.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

**A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.**

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/2022</u> Common: <u>12,161,047</u> Preferred Series A-1: <u>300</u> Preferred Series B-1: <u>5</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to.  *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR-Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
1/4/2023	New Issuance	305	Common	3.28	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/4/2023	New Issuance	305	Common	3.28	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/4/2023	New Issuance	305	Common	3.28	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/4/2023	New Issuance	305	Common	3.28	No	BRANT D. WATSON REVOCABLE LIVING TRUST / BRANT WATSON TRUSTEE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)

2/1/2023	New Issuance	5,047	Common	1.65	No	ANTHONY L.G., PLLC	COMPENSATION FOR LEGAL SERVICES	RESTRICTED	RULE 4(a)(2)
2/2/2023	New Issuance	19,000	Common	1.5	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	COMPENSATION FOR MARKETING SERVICES	RESTRICTED	RULE 4(a)(2)
2/3/2023	New Issuance	322	Common	3.1	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/3/2023	New Issuance	322	Common	3.1	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/3/2023	New Issuance	322	Common	3.1	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/3/2023	New Issuance	322	Common	3.1	No	BRANT D. WATSON REVOCABLE LIVING TRUST / BRANT WATSON TRUSTEE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/8/2023	New Issuance	500,000	Common	1.63	No	M.W JENS REALTY INVESTMENT, LLC / MARK JENS	ISSUANCE OF COMMON STOCK TO REPURCHASE NON-CONTROLLING INTEREST IN SUBSIDIARY	RESTRICTED	RULE 4(a)(2)
2/28/2023	New Issuance	252,357	Common	3	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	CONVERSION FROM DEBT TO EQUITY	RESTRICTED	RULE 4(a)(2)
3/1/2023	New Issuance	19,000	Common	1.5	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	COMPENSATION FOR MARKETING SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2023	New Issuance	295	Common	3.39	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2023	New Issuance	295	Common	3.39	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2023	New Issuance	295	Common	3.39	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2023	New Issuance	295	Common	3.39	No	BRANT D. WATSON REVOCABLE LIVING TRUST / BRANT WATSON TRUSTEE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/13/2023	New Issuance	6,667	Common	1.5	No	MARTEL PELLERIN	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)

3/23/2023	New Issuance	20,000	Common	1.5	No	EMERY WALDON	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
3/23/2023	New Issuance	50,000	Common	1.5	No	EDWARD WALDRON & JULIE WALDRON JTWS / EDWARD AND JULIE WALDRON TRUSTEES	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
3/28/2023	New Issuance	63,334	Common	1.5	No	EDWARD WALDRON JR.	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
4/3/2023	New Issuance	6,667	Common	1.5	No	CHARLES MILLER	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
4/13/2023	New Issuance	17,333	Common	1.5	No	EMPIRE VENTURES HOLDINGS, LLC / JOSEPH SIRIANNI	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
4/19/2023	New Issuance	19,000	Common	1.5	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
4/20/2023	New Issuance	16,667	Common	1.5	No	DONNY PITTMAN	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
4/24/2023	New Issuance	27,000	Common	1.5	No	PAUL SIHON	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
5/2/2023	New Issuance	25,000	Common	1.5	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	COMPENSATION FOR MARKETING SERVICES	RESTRICTED	RULE 4(a)(2)
5/5/2023	New Issuance	442	Common	2.26	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/5/2023	New Issuance	442	Common	2.26	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/5/2023	New Issuance	442	Common	2.26	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/5/2023	New Issuance	442	Common	2.26	No	BRANT D. WATSON REVOCABLE LIVING TRUST / BRANT WATSON TRUSTEE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/5/2023	New Issuance	19,000	Common	2.26	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	COMPENSATION FOR MARKETING SERVICES	RESTRICTED	RULE 4(a)(2)
6/2/2023	New Issuance	16,667	Common	1.5	No	DARYL EBER	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)

6/6/2023	New Issuance	495	Common	2.02	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/6/2023	New Issuance	495	Common	2.02	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/6/2023	New Issuance	495	Common	2.02	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/6/2023	New Issuance	495	Common	2.02	No	BRANT D. WATSON REVOCABLE LIVING TRUST / BRANT WATSON TRUSTEE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/6/2023	New Issuance	19,000	Common	1.5	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	COMPENSATION FOR MARKETING SERVICES	RESTRICTED	RULE 4(a)(2)
6/8/2023	New Issuance	200,000	Common	1.9	No	JOHN RADTKE	EMPLOYEE COMPENSATION	RESTRICTED	RULE 4(a)(2)
7/10/2023	New Issuance	513	Common	1.95	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
7/10/2023	New Issuance	513	Common	1.95	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
7/10/2023	New Issuance	513	Common	1.95	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
7/10/2023	New Issuance	513	Common	1.95	No	BRANT D. WATSON REVOCABLE LIVING TRUST / BRANT WATSON TRUSTEE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
8/1/2023	New Issuance	568	Common	1.76	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
8/1/2023	New Issuance	568	Common	1.76	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
8/1/2023	New Issuance	568	Common	1.76	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
8/1/2023	New Issuance	406	Common	1.83	No	BRANT D. WATSON REVOCABLE LIVING TRUST / BRANT WATSON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)



9/1/2023	New Issuance	576	Common	1.74	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
9/1/2023	New Issuance	576	Common	1.74	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
9/1/2023	New Issuance	576	Common	1.74	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
9/8/2023	New Issuance	17,024	Common	1.76	No	BRANDON POE	BOARD OF DIRECTORS COMPENSATION	RESTRICTED	RULE 4(a)(2)
9/13/2023	New Issuance	60,000	Common	2.15	No	PCG ADVISORY, INC. / JEFF RAMSON	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
9/13/2023	New Issuance	40,000	Common	1.5	No	PROACTIVE CAPITAL PARTNERS, LP / JEFF RAMSON	STOCK ISSUED FOR SERVICE	RESTRICTED	RULE 4(a)(2)
9/21/2023	New Issuance	7000	Common	1.5	No	GLENN & KIM FITZGERALD	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/1/2023	New Issuance	444	Common	2.25	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
10/1/2023	New Issuance	444	Common	2.25	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
10/1/2023	New Issuance	444	Common	2.25	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
10/6/2023	New Issuance	20,000	Common	1.5	No	LEWIS SPERBER	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/6/2023	New Issuance	10,000	Common	1.5	No	STEFAN ARNI AUDOLFSSON	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/6/2023	New Issuance	10,000	Common	1.5	No	HARALDUR TRYGGVASON KLEIN	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/12/2023	New Issuance	20,000	Common	1.5	No	YUPING LIU	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/13/2023	New Issuance	1,000,000	Common	1.5	No	MICHAEL R DIETZEN	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/16/2023	New Issuance	16,667	Common	1.5	No	BEAR CREEK CAPITAL LLC / RAY OLIVER	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/17/2023	New Issuance	20,000	Common	1.5	No	HARRIS SPERBER	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/18/2023	New Issuance	16,667	Common	1.5	No	STEVE SIMON	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/19/2023	New Issuance	95,000	Common	1.5	No	OLYMPUS 3 ACQUISITIONS,	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)

						LLC / CHRIS LEONE			
10/19/2023	New Issuance	20,000	Common	1.5	No	LEWIS SPERBER	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/19/2023	New Issuance	16,667	Common	1.5	No	JILL RENEE ARBOLEDA	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/19/2023	New Issuance	13,334	Common	1.5	No	EMERY WALDRON	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/20/2023	New Issuance	20,000	Common	1.5	No	CHARITY BOYD	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/23/2023	New Issuance	33,333	Common	1.5	No	DARLENE GIMBLE	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/23/2023	New Issuance	20,000	Common	1.5	No	JACOB KRAWZE	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
10/30/2023	New Issuance	33,333	Common	1.5	No	HENRY W VAN VURST IV	STOCK ISSUED FOR CASH	RESTRICTED	RULE 4(a)(2)
11/1/2023	New Issuance	326	Common	3.07	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
11/1/2023	New Issuance	326	Common	3.07	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
11/1/2023	New Issuance	326	Common	3.07	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
11/1/2023	New Issuance	526,325	Common	0.70	No	VICTOR MATUSZEWSKI AND KAREN MATUSZEWSKI	CONVERSION OF DEBT TO EQUITY	RESTRICTED	RULE 4(a)(2)
11/1/2023	New Issuance	20,000	Common	1.50	No	EDWARD & JULIE WALDRON	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
11/10/2023	New Issuance	676,215	Common	0.70	No	JEFFREY ROBERT MEILANDER	CONVERSION OF DEBT TO EQUITY	RESTRICTED	RULE 4(a)(2)
12/1/2023	New Issuance	326	Common	3.07	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
12/1/2023	New Issuance	326	Common	3.07	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
12/1/2023	New Issuance	326	Common	3.07	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
12/8/2023	New Issuance	3,046	Common	3.28	No	BRANDON POE	BOARD OF DIRECTORS COMPENSATION	RESTRICTED	RULE 4(a)(2)
12/8/2023	New Issuance	12,392	Common	3.23	No	THOMAS J. DUGAN	BOARD OF DIRECTORS COMPENSATION	RESTRICTED	RULE 4(a)(2)
12/16/2023	New Issuance	7,989	Common	3.76	No	PATRICK DALY	BOARD OF DIRECTORS COMPENSATION	RESTRICTED	RULE 4(a)(2)

12/23/2023	New Issuance	37,500	Common	2.00	No	WES DE SOUZA	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
1/1/2024	New Issuance	194	Common	5.15	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/1/2024	New Issuance	194	Common	5.15	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/1/2024	New Issuance	194	Common	5.15	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
1/4/2024	New Issuance	2,942	Common	5.17	No	OLYMPUS 3 ACQUISITIONS, LLC / CHRIS LEONE	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
1/8/2024	New Issuance	12,500	Common	2	No	WES DE SOUZA	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
1/30/2024	New Issuance	50,000	Common	2	No	JOSEPH LOMBAS	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
2/1/2024	New Issuance	167	Common	6	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/1/2024	New Issuance	167	Common	6	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/1/2024	New Issuance	167	Common	6	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
2/6/2024	New Issuance	25,000	Common	2	No	JOSHUA J. GOODEN	SECURITY CONVERSION	RESTRICTED	RULE 4(a)(2)
3/1/2024	New Issuance	115	Common	8.72	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2024	New Issuance	115	Common	8.72	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
3/1/2024	New Issuance	115	Common	8.72	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/1/2024	New Issuance	106	Common	9.39	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/1/2024	New Issuance	106	Common	9.39	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/1/2024	New Issuance	106	Common	9.39	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
4/8/2024	New Issuance	60,000	Common	10.78	No	PCG ADVISORY, INC. / JEFF RAMSOM	SERVICES RENDERED	RESTRICTED	RULE 4(a)(2)
4/12/2024	Shares Returned to Treasury	(117,359)	Common	N/A	No	MAXIM PARTNERS LLC / CLIFFORD A. TELLER	SHARES RETURNED TO TREASURY	RESTRICTED	RULE 4(a)(2)

5/1/2024	New Issuance	88	Common	11.31	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/1/2024	New Issuance	88	Common	11.31	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
5/1/2024	New Issuance	88	Common	11.31	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/1/2024	New Issuance	119	Common	8.40	No	JEFFREY K HARRISON	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/1/2024	New Issuance	119	Common	8.40	No	SHAUN OPIE	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
6/1/2024	New Issuance	119	Common	8.40	No	PHYSIOMICS SYSTEMS, LLC / DAN SHELLY	COMPENSATION FOR SCIENTIFIC ADVISORY BOARD SERVICES	RESTRICTED	RULE 4(a)(2)
Shares Outstanding on Date of This Report:  <div style="text-align: right;"><u>Ending Balance</u></div> <u>Ending Balance:</u>  Date <u>6/30/2024</u> Common: <u>16,287,139</u> Preferred Series A-1: <u>300</u> Preferred Series B-1: <u>5</u>									

**Example:** A company with a fiscal year end of December 31<sup>st</sup> 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

**\*\*\*Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

NA

## B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder.  *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
<u>06/01/2023</u>	<u>\$366,030.26</u>	<u>\$750,000</u>	<u>\$0</u>	<u>06/01/25</u>	<u>Holder issued 373,134 Common Stock Purchase Warrants: exercise price \$2.01</u>	<u>Jeffrey Meilander</u>	<u>Loan</u>

**\*\*\*Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

NA

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

##### Organization and Description of the Business

BioStem Technologies, Inc. (hereinafter "the Company"), was incorporated as Aladdin & Company Trading in Utah on July 7, 2006. On March 2, 2009, Aladdin & Company Trading both changed its name to Caribbean Casino & Gaming Corporation and re-domiciled to Florida. Caribbean Casino & Gaming Corporation further changed its name to Caribbean International Holdings, Inc. on January 7, 2013. The Company then changed its name to BioStem Technologies, Inc. on August 28, 2014. The Company is active and currently in good standing with the State of Florida.

The Company's fiscal year end is December 31.

- B. List any subsidiaries, parent company, or affiliated companies.

The Company has one wholly owned, non-operating subsidiary, Nesvik Pharmaceuticals, Inc. Throughout 2022, the Company owed a controlling interest (90%) in an operating subsidiary, Blue Tech Industries, Inc. (d/b/a BioStem Life Sciences, Inc.) or "BSLS". The remaining 10% ownership of BSLS is reported as non-controlling interest ("NCI") within the consolidated financial statements. In January 2023, the Company repurchased the 10% noncontrolling interest in BSLS for 500,000 shares of BSEM Common Stock valued at \$1.63 per share.

Prior to January 2023 the Company owned a controlling interest (90%) in an operating subsidiary, Blue Tech Industries, Inc. (d/b/a BioStem Life Sciences, Inc. or "BSLS"). In January 2023, the Company repurchased the remaining 10% noncontrolling interest ("NCI") in exchange for common stock of the Company. In June 2024, the Company created Auxocell Operations Inc ("Auxocell"), a new subsidiary 100% owned by BioStem Technologies. Auxocell is domiciled in Nevada and holds all of the assets acquired in the Auxocell asset acquisition.

- C. Describe the issuers' principal products or services.

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging our proprietary BioRetain® processing method, we manufacture perinatal tissue allografts at the highest levels of quality. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining natural growth factors and preserving tissue structure. Our allografts are trusted by top clinicians across a range of specialties.

#### 5) Issuer's Facilities

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company owns and operates a 6,100 sq. ft. manufacturing facility with multiple ISO 5 and ISO 7 suites designed for commercial production of human cells, tissues, and cellular based products

("HCT/Ps"). The Company is currently in the process of expanding its manufacturing capacity by doubling its ISO clean room.

The Company also leases certain laboratory and office equipment accounted for as finance leases within the Company's financial statements.

## 6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Jason Matuszewski</u>	<u>Officer, Director and 5% Stockholder</u>	<u>Boca Raton, FL</u>	<u>1,391,592</u> <u>100</u>	<u>Common</u> <u>Preferred A-1</u>	<u>8.54%</u> <u>33.33%</u>	_____
<u>Andrew VanVurst</u>	<u>Officer, Director and 5% Stockholder</u>	<u>Lighthouse Point, FL</u>	<u>1,692,348</u> <u>100</u>	<u>Common</u> <u>Preferred A-1</u>	<u>10.39%</u> <u>33.33%</u>	_____
<u>Henry VanVurst</u>	<u>Owner of more than 5%</u>	<u>Fort Lauderdale, FL</u>	<u>1,258,745</u> <u>100</u>	<u>Common</u> <u>Preferred A-1</u>	<u>7.73%</u> <u>33.33%</u>	_____
<u>Michael Fortunato</u>	<u>Officer, Director and 5% Stockholder</u>	<u>Pittsburgh, PA</u>	<u>105,000</u>	<u>Common</u>	<u>&lt;1%</u>	_____
<u>Brandon Poe</u>	<u>Director &lt;5%</u>	<u>San Diego, CA</u>	<u>33,878</u>	<u>Common</u>	<u>&lt;1%</u>	_____
<u>Kenneth Warrington</u>	<u>Director &lt;5%</u>	<u>Gainesville, FL</u>	<u>7,462</u>	<u>Fully Vested Common</u>	<u>&lt;1%</u>	_____

				<u>Stock Options</u>		
<u>Patrick Daly</u>	<u>Director &lt;5%</u>	<u>Raleigh, NC</u>	<u>7,989</u>	<u>Common</u>	<u>&lt;1%</u>	
<u>Thomas Dugan</u>	<u>Director &lt;5%</u>	<u>Ponte Vedra Beach, FL</u>	<u>12,392</u>	<u>Common</u>	<u>&lt;1%</u>	
<u>Michael Dietzen</u>	<u>Owner of &gt;5%</u>	<u>Fort Lauderdale, FL</u>	<u>1,025,000</u>	<u>Common</u>	<u>6.28%</u>	

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Jessica Haggard, Esq.  
Firm: Anthony, Linder & Cacomanolis  
Address 1: 1700 Palm Beach Lakes Blvd., Suite 820  
Address 2: West Palm Beach, FL 33401  
Phone: (561) 514-0936  
Email: JHaggard@ALClaw.com

### Accountant or Auditor

Name: Ilyssa Blum  
Firm: Marcum, LLP  
Address 1: 201 East Las Olas Boulevard, 21st Floor  
Address 2: Ft. Lauderdale, FL 33301  
Phone: (954) 320-8020  
Email: Ilyssa.Blum@marcumllp.com

### Investor Relations

Name: Jeff Ramson  
Firm: PCG Advisory  
Address 1: 950 Third Avenue, Suite 2700  
Address 2: NY, NY 10022  
Phone: (646) 863-6341  
Email: jramson@pcgadvisory.com

*All other means of Investor Communication:*

X (f/k/a Twitter): X BSEM Twitter ([https://twitter.com/BSEM\\_Tech](https://twitter.com/BSEM_Tech))  
Discord: \_\_\_\_\_  
LinkedIn: X [BSEM LinkedIn Page](#)  
Facebook: \_\_\_\_\_  
[Other - Instagram] X [BSEM Instagram Link](#)



#### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: NA  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### 9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Michael Fortunato, CPA  
Title: CFO  
Relationship to Issuer: Officer

B. The following financial statements were prepared in accordance with:

- ☐ IFRS  
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Michael A. Fortunato, CPA  
Title: CFO  
Relationship to Issuer: Officer

Describe the qualifications of the person or persons who prepared the financial statements: The CFO is a licensed CPA and has over 30 years of experience in accounting and financial reporting.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

#### **Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.

- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Jason V. Matuszewski certify that:

1. I have reviewed this Disclosure Statement for BioStem Technologies, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 28, 2024

/s/ Jason V. Matuszewski [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

### *Principal Financial Officer:*

I, Michael A. Fortunato certify that:

1. I have reviewed this Disclosure Statement for BioStem Technologies, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 28, 2024

/s/ Michael A. Fortunato [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")



---

BIOSTEM TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS

---

**For the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited)**

## Table of Contents

Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023	2
Unaudited Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023	3
Unaudited Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the Three and Six Months Ended June 30, 2024 and 2023	4
Unaudited Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023	6
Condensed Notes to the Unaudited Consolidated Financial Statements	7

**BioStem Technologies, Inc. and Subsidiaries**  
**Consolidated Balance Sheets**

	<u>June 30, 2024</u>	<u>December 31, 2023</u>
	<u>(unaudited)</u>	
<b>Current Assets</b>		
Cash	\$ 6,572,126	\$ 239,406
Accounts receivable, net	78,190,570	11,371,730
Inventory, net	1,370,749	658,678
Prepaid expenses and other assets	1,372,849	329,239
Total current assets	<u>87,506,294</u>	<u>12,599,053</u>
<b>Long-Term Assets</b>		
Property and equipment, net	1,443,677	1,154,856
Construction-in-process	43,423	202,700
Right-of-use asset, net	318,334	11,443
Intangible assets, net	285,870	347,604
Goodwill	244,635	244,635
Other assets	616,347	-
Total assets	<u>\$ 90,458,580</u>	<u>\$ 14,560,291</u>
<b>Current Liabilities</b>		
Accounts payable and accrued expenses	\$ 8,077,526	\$ 1,391,711
Bona fide services fee payable (Note 4)	60,792,973	7,787,211
Accrued interest	1,829,534	1,697,787
Short-term finance lease	-	8,988
Operating lease liabilities	99,567	-
Notes payable, net of discount	4,083,660	4,445,782
Other current liabilities	587,054	289,409
Total current liabilities	<u>75,470,314</u>	<u>15,620,888</u>
<b>Long-Term Liabilities</b>		
Operating lease liabilities, less current portion	235,598	-
Finance lease liabilities, less current portion	-	3,294
Notes payable, less current portion	142,437	265,635
Other long-term liabilities, less current portion	-	14,850
Total long-term liabilities	<u>378,035</u>	<u>283,779</u>
Total liabilities	<u>75,848,349</u>	<u>15,904,667</u>
<b>Commitments and contingencies (Note 10)</b>		
<b>Stockholders' Equity (Deficit)</b>		
Series A-1 convertible preferred stock, \$0.001 par value authorized, 300 shares; issued and outstanding, 300 shares as of June 30, 2024 and December 31, 2023.	-	-
Series B-1 convertible preferred stock, \$0.001 par value authorized, 500,000 shares; issued and outstanding 5 shares as of June 30, 2024 and December 31, 2023.	-	-
Common stock, \$0.001 par value authorized, 975,000,000 shares issued and outstanding 16,287,139 and 16,214,390 shares as of June 30, 2024 and December 31, 2023.	16,288	16,215
Additional paid-in capital	50,717,986	44,306,872
Treasury stock, 18,000 shares at cost	(43,346)	(43,346)
Accumulated deficit	(36,080,697)	(45,624,117)
Total stockholders' equity (deficit)	<u>14,610,231</u>	<u>(1,344,376)</u>
Total liabilities and stockholders' equity (deficit)	<u>\$ 90,458,580</u>	<u>\$ 14,560,291</u>

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

**BioStem Technologies, Inc. and Subsidiaries**  
**Consolidated Statements of Operations**  
(Unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2024	June 30, 2023	June 30, 2024	June 30, 2023
Revenue, net	\$ 74,491,996	\$ 1,068,400	\$ 116,396,209	\$ 1,644,503
Cost of goods sold	3,747,896	206,104	5,972,600	307,253
Gross profit	70,744,100	862,296	110,423,609	1,337,250
Operating Expenses:				
Sales and marketing expenses	58,997,880	590,975	89,549,433	1,095,373
General and administrative expenses	2,787,822	2,863,787	7,183,774	6,169,423
Research and development expenses	85,154	60,904	155,901	130,632
Depreciation and amortization expense	54,113	60,018	107,778	118,363
Total operating expenses	61,924,969	3,575,684	96,996,886	7,513,791
Income (loss) from operations	8,819,131	(2,713,388)	13,426,723	(6,176,541)
Other Income (Expense):				
Interest expense	(219,051)	(143,040)	(382,993)	(263,466)
Other expense (income)	(115)	1,402	(1,686)	4,893
Other expense, net	(219,166)	(141,638)	(384,679)	(258,573)
Income (loss) from operations before income taxes	8,599,965	(2,855,026)	13,042,044	(6,435,114)
Income tax expense	2,313,937	-	3,498,624	-
Net Income (loss)	\$ 6,286,028	\$ (2,855,026)	\$ 9,543,420	\$ (6,435,114)
Basic net income (loss) per share attributable to common stockholders	\$ 0.39	\$ (0.22)	\$ 0.59	\$ (0.50)
Diluted net income (loss) per share attributable to common stockholders	\$ 0.30	\$ (0.22)	\$ 0.46	\$ (0.50)
Basic weighted average common shares outstanding	16,296,689	13,259,109	16,306,640	12,917,247
Diluted weighted average common shares outstanding	20,919,096	13,259,109	20,657,707	12,917,247

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

BioStem Technologies, Inc. and Subsidiaries  
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)  
(Unaudited)

	Series A-1		Series B-1		Common Stock		Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount				
<b>Six Months Ended June 30, 2024</b>										
Balance as of December 31, 2023	300	\$ -	5	\$ -	16,214,390	\$ 16,215	\$ 44,306,872	\$ (43,346)	\$ (45,624,117)	\$ (1,344,376)
Stock based compensation-stock options	-	-	-	-	-	-	3,932,101	-	-	3,932,101
Issuance of common stock for services	-	-	-	-	62,166	62	270,310	-	-	270,372
Conversion of debt and accrued interest to common stock	-	-	-	-	2,942	3	15,207	-	-	15,210
Issuance of common stock for cash received on warrant exercises	-	-	-	-	125,000	125	249,880	-	-	250,005
Warrant issued for prepaid services	-	-	-	-	-	-	1,943,500	-	-	1,943,500
Common stock repurchased	-	-	-	-	(117,359)	(117)	116	-	-	(1)
Net income	-	-	-	-	-	-	-	-	9,543,420	9,543,420
<b>Balance as of June 30, 2024</b>	<b>300</b>	<b>\$ -</b>	<b>5</b>	<b>\$ -</b>	<b>16,287,139</b>	<b>\$ 16,288</b>	<b>\$ 50,717,986</b>	<b>\$ (43,346)</b>	<b>\$ (36,080,697)</b>	<b>\$ 14,610,231</b>

	Series A-1		Series B-1		Common Stock		Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Noncontrolling Interest	Total Stockholders' Deficit
	Shares	Amount	Shares	Amount	Shares	Amount					
<b>Six Months Ended June 30, 2023</b>											
Balance as of December 31, 2022	300	\$ -	5	\$ -	12,161,047	\$ 12,162	\$ 33,095,921	\$ (43,346)	\$ (37,141,133)	\$ 126,444	\$ (3,949,952)
Stock based compensation-stock options	-	-	-	-	-	-	3,463,661	-	-	-	3,463,661
Issuance of common stock for services	-	-	-	-	113,834	114	404,805	-	-	-	404,919
Issuance of common stock for cash	-	-	-	-	249,333	249	373,751	-	-	-	374,000
Conversion of debt and accrued interest to common stock	-	-	-	-	252,357	252	252,105	-	-	-	252,357
Issuance of shares for purchase of noncontrolling interest	-	-	-	-	500,000	500	125,944	-	-	(126,444)	-
Issuance of shares and warrants in legal settlement	-	-	-	-	200,000	200	639,300	-	-	-	639,500
Warrant issued with note payable	-	-	-	-	-	-	305,310	-	-	-	305,310
Net loss	-	-	-	-	-	-	-	-	(6,435,114)	-	(6,435,114)
<b>Balance as of June 30, 2023</b>	<b>300</b>	<b>\$ -</b>	<b>5</b>	<b>\$ -</b>	<b>13,476,571</b>	<b>\$ 13,477</b>	<b>\$ 38,660,797</b>	<b>\$ (43,346)</b>	<b>\$ (43,576,247)</b>	<b>\$ -</b>	<b>\$ (4,945,319)</b>

See the Condensed Notes to the Unaudited Consolidated Financial Statements.

BioStem Technologies, Inc. and Subsidiaries  
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)  
(Unaudited)

	Series A-1		Series B-1		Common Stock					Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	
<b>Three Months Ended June 30, 2024</b>										
Balance as of March 31, 2024	300	\$ -	5	\$ -	16,343,496	\$ 16,344	\$ 47,850,007	\$ (43,346)	\$ (42,366,725)	\$ 5,456,280
Stock based compensation-stock options	-	-	-	-	-	-	746,817	-	-	746,817
Issuance of common stock for services	-	-	-	-	61,002	61	177,546	-	-	177,607
Warrant issued for prepaid services	-	-	-	-	-	-	1,943,500	-	-	1,943,500
Common stock repurchased	-	-	-	-	(117,359)	(117)	116	-	-	(1)
Net income	-	-	-	-	-	-	-	-	6,286,028	6,286,028
Balance as of June 30, 2024	300	\$ -	5	\$ -	16,287,139	\$ 16,288	\$ 50,717,986	\$ (43,346)	\$ (36,080,697)	\$ 14,610,231
	Series A-1		Series B-1		Common Stock					Total Stockholders' Deficit
	Shares	Amount	Shares	Amount	Shares	Amount	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	
<b>Three Months Ended June 30, 2023</b>										
Balance as of March 31, 2023	300	\$ -	5	\$ -	13,105,186	\$ 13,106	\$ 36,191,326	\$ (43,346)	\$ (40,721,221)	\$ (4,560,135)
Stock based compensation-stock options	-	-	-	-	-	-	1,158,507	-	-	1,158,507
Issuance of common stock for services	-	-	-	-	62,052	62	202,463	-	-	202,525
Issuance of common stock for cash	-	-	-	-	109,333	109	163,891	-	-	164,000
Issuance of shares and warrants in legal settlement	-	-	-	-	200,000	200	639,300	-	-	639,500
Warrant issued with note payable	-	-	-	-	-	-	305,310	-	-	305,310
Net loss	-	-	-	-	-	-	-	-	(2,855,026)	(2,855,026)
Balance as of June 30, 2023	300	\$ -	5	\$ -	13,476,571	\$ 13,477	\$ 38,660,797	\$ (43,346)	\$ (43,576,247)	\$ (4,945,319)

See the Condensed Notes to the Unaudited Consolidated Financial Statements.



**BioStem Technologies, Inc. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
(Unaudited)

	<b>Six Months Ended,</b>	
	<b>June 30, 2024</b>	<b>June 30, 2023</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net income (loss)	\$ 9,543,420	\$ (6,435,114)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation expense	46,044	55,730
Amortization expense	61,734	58,245
Amortization of debt discount	172,886	-
Amortization of right-of-use asset	33,510	-
Stock-based compensation - stock options	3,932,101	3,463,661
Issuance of common stock for services	270,372	404,919
Stock and warrants issued for legal settlement	-	639,500
Amortization of prepaid services paid with common stock warrants	256,864	-
Provision for credit losses	175,000	-
Changes in operating assets and liabilities:		
Accounts receivable	(66,993,840)	(128,131)
Inventory	(712,071)	(103,052)
Prepaid expenses and other assets	26,679	(4,955)
Accounts payable and accrued expenses	6,685,815	259,818
Accrued interest	131,747	149,321
Bona fide service fee payable	53,005,762	-
Other current liabilities	270,513	14,892
Operating lease liabilities	(5,236)	-
Net cash provided by (used in) operating activities	<u>6,901,300</u>	<u>(1,625,166)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchases of property and equipment	(175,588)	(64,749)
Purchases of intangible assets	-	(105,000)
Net cash used in investing activities	<u>(175,588)</u>	<u>(169,749)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Borrowings on notes payable	-	1,080,230
Repayments on notes payable	(642,996)	(103,353)
Repayments on finance leases	-	(4,384)
Issuance of common stock for cash	-	374,000
Issuance of common stock for warrant exercise	250,005	-
Common stock repurchased	(1)	-
Net cash provided by (used in) financing activities	<u>(392,992)</u>	<u>1,346,493</u>
Cash, cash equivalents:		
Net change during the period	6,332,720	(448,422)
Balance, beginning of period	239,406	772,136
Balance, end of period	<u>\$ 6,572,126</u>	<u>\$ 323,714</u>
<b>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</b>		
Cash paid for interest	<u>\$ 78,360</u>	<u>\$ 116,502</u>
<b>SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</b>		
Conversion of debt and accrued interest to shares of common stock	<u>\$ 15,210</u>	<u>\$ 252,357</u>
Issuance of shares for repurchase of noncontrolling interest	<u>\$ -</u>	<u>\$ 126,444</u>
Issuance of warrant for prepaid services	<u>\$ 1,943,500</u>	<u>\$ -</u>
Right-of-use asset and liability	<u>\$ 340,401</u>	<u>\$ -</u>
Warrant issued with note payable	<u>\$ -</u>	<u>\$ 305,310</u>
Construction-in-process transferred to property and equipment	<u>\$ 159,277</u>	<u>\$ -</u>

See the Condensed Notes to the Unaudited Consolidated Financial Statements

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

**Note 1 - Organization and Description of Business**

BioStem Technologies, Inc. (hereinafter “the Company”), was incorporated as Aladdin & Company Trading in Utah on July 7, 2006. Aladdin & Company Trading later changed its name to Caribbean Casino & Gaming Corporation and re-domiciled in Florida on March 2, 2009. On January 7, 2013, Caribbean Casino & Gaming Corporation changed its name to Caribbean International Holdings, Inc. on January 7, 2013. On August 28, 2014, the Company changed its name to BioStem Technologies, Inc.

Since 2018, the Company’s primary business is the development, manufacture, and sale of tissue allografts for the advanced wound care market with a focus on the treatment of diabetic, pressure and venous ulcers. The Company markets and distributes products directly to medical professionals, such as podiatrists and plastic surgeons, through direct and indirect salesforces and indirectly through distributors.

The Company’s fiscal year end is December 31.

**Note 2 - Summary of Significant Accounting Policies**

**Basis of Presentation and Consolidation**

The consolidated financial statements of the Company are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair statement of the Company’s consolidated financial position and results of operations for the periods presented. Certain information and disclosures included in these interim consolidated financial statements have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (“SEC”) rules. These condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, as filed with the Over-the-Counter (“OTC”) Market on April 24, 2024. The results for the six month periods ended June 30, 2024 and 2023, are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or periods.

The accompanying consolidated financial statements are prepared in accordance with US GAAP and include the accounts of BioStem Technologies, Inc. and all its wholly- owned subsidiaries BioStem Life Sciences, Inc. and Nesvik Pharmaceuticals, Inc, which is currently inactive. All intercompany transactions have been eliminated in consolidation.

Prior to January 2023 the Company owned a controlling interest (90%) in an operating subsidiary, Blue Tech Industries, Inc. (d/b/a BioStem Life Sciences, Inc. or “BSLS”). In January 2023, the Company repurchased the remaining 10% noncontrolling interest (“NCI”) in exchange for common stock of the Company. In June 2024, the Company created Auxocell Operations Inc (“Auxocell”), a new subsidiary 100% owned by BioStem Technologies. Auxocell is domiciled in Nevada and holds all of the assets acquired in the Auxocell asset acquisition (see Note 7).

**Use of Estimates**

The preparation of these interim unaudited consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.

Such estimates and assumptions impact both assets and liabilities, including but not limited to the estimated fair value of stock-based payments and the valuation of deferred tax assets.

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, actual results could differ significantly from estimates.

**Risks and Uncertainties**

The Company's operations are subject to risk and uncertainties including financial, operational, regulatory, and other risks including the potential risk of business failure.

The Company has experienced, and in the future expects to continue to experience, variability in its sales and earnings. The factors expected to contribute to this variability include, among others: (i) the uncertainty associated with the commercialization and ultimate success of the Company's products; (ii) competition inherent in the markets where products are expected to be sold; (iii) general economic conditions; and (iv) the related volatility of prices pertaining to the cost of sales.

The Company has a high customer concentration in which our revenue and accounts receivable come from a limited number of customers. Accordingly, each year there may be a small number of customers from whom we generate our revenue. These customers may not be repeat purchasers and in each year, it may be a different single purchaser or small number of purchasers from which we generate a large percentage of our revenues. The Company relies on these purchasers and there is a risk that these purchasers may be unable to make payment under their obligations to us, thereby affecting our revenues. In September 2023, the Company executed a distribution and services agreement with a large medical distributor located in the United States for the distribution of the Company's Amnio Wrap 2 products. During the three and six months ended June 30, 2024, this customer accounted for approximately 99% of our total revenues (see Note 4).

**Summary of Significant Accounting Policies**

The significant accounting policies applied in the Company's audited financial statements, as disclosed in its annual financial report filed with the OTC on April 24, 2024, are applied consistently in these unaudited interim consolidated financial statements.

**Recently Issued and Adopted Accounting Pronouncements**

In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, *Financial Instruments—Credit Losses (Topic 326)*, which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This standard was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years with early adoption permitted. In November 2019, the FASB issued ASU No. 2019-10, *Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates*, which defers the effective date of Topic 326. Topic 326 was effective for the Company beginning January 1, 2023. The Company adopted this ASU January 1, 2023 and it did not have a significant impact on its consolidated financial statements and related disclosures.

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

**Note 3 - Inventory**

Inventory is stated at the lower of cost or estimated net realizable value. Inventory cost is determined by the first-in, first-out (“FIFO”) basis. Inventory costs include raw materials, labor and operating overhead which includes supplies, depreciation and amortization of leased lab equipment and other related costs.

The Company performs an assessment of the recoverability of inventory cost during each reporting period, and it provides an allowance for slow-moving, excess, and obsolete inventories to their estimated net realizable value in the period in which the need for an allowance is first identified. Such impairment charges are recorded within cost of goods sold. As of June 30, 2024 and December 31, 2023, the Company did not record any such impairments.

The table below presents the Company’s inventory values, by category, as of June 30, 2024 and December 31, 2023, respectively:

	<b>June 30, 2024</b>	<b>December 31, 2023</b>
Raw Materials	\$ 290,385	\$ 69,473
Finished Goods	1,080,364	589,205
Total, net realizable value	<b>\$ 1,370,749</b>	<b>\$ 658,678</b>

**Note 4 - Revenue Recognition**

The Company records revenue from product sales in accordance with ASC 606 (“ASC 606”), *Revenue from Contracts with Customers*.

The Company recognizes revenue from product sales at a point in time when control of the Company’s product has transferred to the customer, which generally occurs upon shipment. Shipping and handling costs are included as a component of revenue. Shipping and handling costs are passed through to customers with an equal offsetting amount included in cost of goods sold.

Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for the product, which is generally fixed. Based on prior experience, and the nature of the product, variable consideration resulting from product discounts is not material.

Returns from customers are not accepted. Accordingly, there is no provision for sales returns recorded for any period presented.

***Distribution and Services Agreement***

In September 2023, the Company executed a distribution and services agreement (“D&S Agreement”) with a large medical distributor located in the United States (the “Distributor”) for the distribution of the Company’s Amnio Wrap 2 (“AW2”) products. The Company licenses the rights to manufacture and commercialize AW2 from an unrelated party and in conjunction with the licensing arrangement, pays a per square centimeter license fee for all AW2 products sold by the Distributor.

The Distributor purchases the AW2 products from the Company at a fixed fee per square centimeter (“Sales Price”) with no right of return. Separately, the Distributor invoices the Company monthly for distinct sales, marketing and distribution services it provides on behalf of the Company (“Bona Fide Services Fee” or “BFSF”).

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

The BFSF is consideration payable to the Distributor for a distinct service the Distributor is providing to the Company. In accordance with ASC 606-10-32-26, such distinct services provided by a customer are accounted for in the same way that other purchases from suppliers would be accounted for. If the amount of consideration payable to the customer exceeds the fair value of the distinct good or service that the entity receives from the customer, then the entity shall account for such an excess as a reduction of the transaction price.

The Company has determined that the fair value of the BFSF does not exceed the consideration paid to the Distributor for these services. Therefore, the Company records, as revenue, the Sales Price per cm<sup>2</sup> for all AW2 products sold to the Distributor upon shipment and recognizes the BFSF as an operating expense within sales and marketing expenses.

During the three and six months ended June 30, 2024, revenues earned from the shipment of AW2 under the distribution and services agreement were \$74,423,600 and \$115,558,500, respectively, and BFSF was \$29,839,998 and \$87,792,126 which is included in sales and marketing expenses on the consolidated statement of operations. During the three and six months ended June 30, 2024, we incurred license fees for the AW2 products sold by the Distributor of \$1,817,400 and \$4,751,200, respectively, which are included in cost of goods sold on the consolidated statements of operations. We did not incur such revenues or expenses during the three and six months ended June 30, 2023.

As of June 30, 2024 and December 31, 2023, accounts receivable due under this arrangement were \$78,073,127 and \$11,126,598, respectively, and amounts due to the Distributor for BFSF were \$60,792,973 and \$7,787,211, respectively, which has been presented as Bona Fide Services Fee payable on the consolidated balance sheets. The BFSF is paid upon receipt of outstanding accounts receivable. As of June 30, 2024 and December 31, 2023, accrued license fees were \$3,097,950 and \$521,475, respectively, which has been presented within accounts payable and accrued expenses on the consolidated balance sheets.

***Disaggregation of Revenue***

The following table provides information about revenue disaggregated by major products categories:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2024	2023	2024	2023
Membrane product net revenue	\$ 74,491,996	\$ 304,165	\$ 115,708,803	\$ 323,315
Cord product net revenue	-	764,235	687,406	1,321,488
Total net revenue	\$ 74,491,996	\$ 1,068,400	\$ 116,396,209	\$ 1,644,803

***Contract Balances***

The following table provides information about the Company's accounts receivable and contract liabilities from contracts with customers as of June 30, 2024 and December 31, 2023:

	June 30, 2024	December 31, 2023
Accounts receivable, net	\$ 78,190,570	\$ 11,371,730
Contract liabilities	\$ 8,812	\$ 8,731

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

Accounts receivable represent the Company's unconditional rights to consideration for product shipped. Contract liabilities represent amounts collected from customers upfront upon placement of an order for product which is included in other current liabilities in the Company's unaudited consolidated balance sheets. The Company generally recognizes revenue from contract liabilities within the following fiscal year.

The Company expects to collect the outstanding balance of current accounts receivable, net within the next twelve months. Accounts receivable, net are carried at the original invoice amount less an allowance for credit losses which is based upon historical loss patterns, the number of days that billings are past due, an evaluation of the potential risk of loss associated with delinquent accounts and current market conditions and reasonable and supportable forecasts of future economic conditions to form adjustments to historical loss patterns. Accounts receivable, net are considered impaired and written-off when it is probable that all contractual payments due will not be collected in accordance with the terms of the agreement. As a result of this analysis, the Company has reserved for estimated credit losses of \$223,166 and \$48,166 as of June 30, 2024 and December 31, 2023, respectively.

**Contract Costs**

The Company incurs incremental costs to obtain contracts with its customers. These costs consist primarily of sales commissions paid to our sales force. As the expected period of amortization is not expected to exceed one year, the Company has elected to expense such costs as incurred.

**Cost of Goods Sold**

Cost of goods sold represents costs directly related to the production of the Company's products. Products sold are typically shipped directly to the customer with costs associated with shipping and handling included as a component of the cost of goods sold. Costs associated with any inventory write-downs resulting from quarterly physical inventory counts are also included in the cost of goods sold.

**Note 5 - Net Income (Loss) Per Share**

Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period. Diluted earnings per share is computed by adjusting the weighted-average number of common shares outstanding to include outstanding common stock options, restricted stock awards, warrants to purchase common stock, convertible preferred stock, and common stock issuable in connection with convertible notes. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.

	Three Months Ended		Six Months Ended	
	June 30, 2024	June 30, 2023	June 30, 2024	June 30, 2023
Net income (loss) available to common shareholders (numerator)	\$ 6,286,028	\$ (2,855,026)	\$ 9,543,420	\$ (6,435,114)
Weighted-average number of common shares (denominator)	16,296,689	13,259,109	16,306,640	12,917,247
Basic earnings (loss) per common share	\$ 0.39	\$ (0.22)	\$ 0.59	\$ (0.50)
Weighted-average number of common shares	16,296,689	13,259,109	16,306,640	12,917,247
Potential shares of common stock arising from stock options, warrants, and unvested RSU's	4,622,407	-	4,351,067	-
Total shares-diluted (denominator)	20,919,096	13,259,109	20,657,707	12,917,247
Diluted earnings (loss) per common share	\$ 0.30	\$ (0.22)	\$ 0.46	\$ (0.50)
Anti-dilutive weighted shares excluded from the calculation of diluted loss per common share	-	7,246,882	-	7,246,882

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

**Note 6 – Property, Equipment, and Construction-in-Process**

The following table presents property, equipment, and construction-in-process as of June 30, 2024 and December 31, 2023:

	June 30, 2024	December 31, 2023
Building	\$ 433,448	\$ 433,448
Building improvements	1,043,643	694,134
Land	75,000	75,000
Machinery and equipment	909,192	930,334
Computer and office equipment	64,702	64,702
Furniture and fixtures	68,066	68,066
Total Property and equipment	2,594,051	2,265,684
Less: Accumulated depreciation	(1,150,374)	(1,110,828)
Total Property and equipment, net	\$ 1,443,677	\$ 1,154,856
Construction-in-process	\$ 43,423	\$ 202,700

Depreciation expenses was \$21,868 and \$27,139 for the three months ended June 30, 2024 and 2023, respectively. Depreciation expense was \$46,044 and \$55,730 for the six months ended June 30, 2024 and 2023, respectively.

**Note 7 – Intangible Assets Other Than Goodwill**

The Company's intangible assets were acquired in business combinations or asset acquisitions and are recognized at fair value using generally accepted valuation methods deemed appropriate for the type of intangible asset acquired and reported net of accumulated amortization, separately from goodwill. On February 23, 2023, the Company entered into an agreement to acquire certain intangible assets of Auxocell Laboratories, Inc. ("Auxocell"). The purchase price for Auxocell was \$105,000 paid in cash which was allocated to the intangible assets acquired, intellectual property. This transaction was accounted for as an asset acquisition.

Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets include developed technology, intellectual property, and customer relationships.

Amortization of intangible assets with finite lives is calculated on the straight-line method based on the following estimated useful lives:

Website and software development costs	5 years
Intellectual property	5 - 7 years
Customer relationships	7 years

Acquired intangible assets with finite useful lives are reviewed for impairment when events or changes in circumstances suggest that the carrying value of these assets may not be recoverable. No impairment losses were recognized by the Company for the six months ended June 30, 2024 or 2023.

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

The following table presents intangible assets other than goodwill as of June 30, 2024 and December 31, 2023:

As of June 30, 2024			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Intellectual property	\$ 152,000	\$ 67,167	\$ 84,833
Website & software development costs	225,907	83,870	142,037
Customer relationships	354,000	295,000	59,000
Total	\$ 731,907	\$ 446,037	\$ 285,870

  

As of December 31, 2023			
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Intellectual property	\$ 152,000	\$ 53,307	\$ 98,693
Website & software development costs	225,907	61,279	164,628
Customer relationships	354,000	269,717	84,283
Total	\$ 731,907	\$ 384,303	\$ 347,604

During each of the six months ended June 30, 2024 and June 30, 2023, respectively, amortization expense was \$61,734 and \$58,245, respectively. During each of the three months ended June 30, 2024 and June 30, 2023, respectively, amortization expense was \$30,867, and \$30,878, respectively.

Future expected amortization expense of intangible assets is as follows:

Year Ending December 31,		
2024 (remaining)	\$	61,732
2025		104,372
2026		66,181
2027		50,085
2028		3,500
Total	\$	285,870



**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

**Note 8 – Notes Payable**

The following table presents the carrying value of the Company's notes payable as of June 30, 2024 and December 31, 2023:

	June 30, 2024	December 31, 2023
On July 27, 2018, the Company entered into a Bridge Loan Agreement and Promissory Note, with an interest rate of 0.50% per month for the first six months and 0.75% per month through the Maturity Date of July 27, 2019. This agreement has not been repaid on the maturity date and is currently in default (1).	\$ 1,000,000	\$ 1,000,000
On October 5, 2018, the Company entered into a Bridge Loan Agreement and Promissory Note, with an interest rate of 0.50%, per month for the first six months and 0.75% per month through the Maturity Date of October 5, 2019. This agreement has not been repaid on the maturity date and is currently in default (1).	2,000,000	2,000,000
On April 29, 2022, the Company entered an \$850,000 mortgage note at 8.25 % per annum with a maturity date of May 1, 2024. Between June 1, 2022, and the maturity date, the Company is required to make monthly interest only payments of \$6,021 with a balloon payment of \$850,000 due May 1, 2024. On May 1, 2024 the note was reviewed and extended with a new maturity date of May 1, 2025 at 10.00% per annum. The Company is required to make monthly interest only payments of \$7,083 with a ballon payment of \$850,000 due May 1, 2025. The loan is secured by the corporate headquarters building with an approximate net book value of \$337,000.	850,000	850,000
On April 30, 2020, the Company obtained a \$263,400 Paycheck Protection Program ("PPP") Term Note from a financial institution. Loan was subject to forgiveness if certain criteria were met, if not, due in five years with 1% of interest. Payments were deferred for the first seven months of the loan. In 2021, \$193,354 of the note was forgiven and the remaining balance will be repaid. This was paid in full as of June 30, 2024.	-	26,462
On May 18, 2020, the Company obtained a \$150,000 Economic Injury Disaster Loan. Installment payments, including principal and interest, of \$731 monthly, began 30 months from the promissory note or November 18, 2022. Interest will accrue at an annual rate of 3.75%.	150,000	150,000
The Company obtained three seperate loans from the same lender and aggregate principal of \$284,719. The loans bore interest at a rate of 23.0% per annum. The Company was required to make minimum monthly payments of \$18,831. The loans matured at various times through August 2024. The loans were secured by the Company's receivables, inventory and other tangible and intangible assets. These loans were paid in full as of June 30, 2024.	-	80,748

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

On June 1, 2023, the Company issued a promissory note in the amount of \$750,000 with an interest rate of 12.0% per annum. Between July 1, 2023 and the maturity date of May 25, 2025, the Company is required to make minimum monthly payments of principal and interest of \$35,305 monthly. The Note is an unsecured obligation (2).	366,030	549,427
On September 13, 2023, the Company entered an \$279,800 financing arrangement with a lender. The financing was collateralized by a portion of the Company's outstanding accounts receivable. The Company was required to make 36 weekly payments of \$7,772. This was paid in full as of June 30, 2024.	-	155,444
On September 14, 2023, the Company entered an \$278,000 financing arrangement with a lender. The financing was collateralized by a portion of the Company's outstanding accounts receivable. The Company was required to make 36 weekly payments of \$7,723. This was paid in full as of June 30, 2024.	-	162,155
In July 2023, the Company issued a promissory note in the amount of \$50,000 with an interest rate of 1% per annum and a maturity date of September 30, 2023 extended to December 2023. During the six months ended June 30, 2024, \$15,000 of principal and \$310 of accrued interest were converted to shares of common stock and the remaining principal balance of \$35,000 was paid in full on January 4, 2024.	-	50,000
Total notes payable	4,366,030	5,024,236
Less: unamortized discounts	(139,933)	(312,819)
Total notes payable	4,226,097	4,711,417
Less : current portion of notes payable	(4,083,660)	(4,445,782)
Notes payable-long-term	\$ 142,437	\$ 265,635

<sup>(1)</sup> In August 2019, the Company received notice from GMA Bridge Fund, LLC that the Company is in default for the loan that matured on July 27, 2019, for non-payment and gave the Company notice that the note which matured on October 5, 2019, was also in default. The Company continues to accrue interest on these loans.

<sup>(2)</sup> In connection with the issuance of the \$750,000 promissory note, the lender received 373,134 common stock warrants with an exercise price of \$2.00 and exercise period of five years. The Company recorded a debt discount of \$305,310 based on the relative fair value of the warrants. The fair value of the warrants was determined using a Black-Scholes pricing model and the following assumptions: expected term 3 years, risk free interest rate of 3.98%, and volatility of 107.74%.

Future maturities required on the notes payable are as follows:

<b>Year Ending December 31,</b>	
2024 (remaining)	\$ 4,223,593
2025	3,774
2026	3,918
2027	4,068
2028	4,223
Thereafter	126,454
Total	4,366,030
Less: unamortized discounts	(139,933)
Total notes payable	\$ 4,226,097

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

**Note 9 – Stockholders' Equity (Deficit)**

***Series A-1 Convertible Preferred Shares***

The Company has designated 300 shares of preferred stock with a par value of \$.001 as “Series A-1 Convertible Preferred Shares”.

The Series A-1 Convertible Preferred Shares entitle their holders to a number of votes equal to the number of shares issuable upon conversion times 2,000,000 granting the holders of Series A-1 Convertible Preferred Shares, as a group, effective control of the Company.

Each Series A-1 Convertible Preferred Shares are convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but not in part, into 300 shares of common stock.

Holders of Series A-1 Convertible Preferred Shares are not entitled to receive dividends, out of assets legally available thereof, prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation.

As of June 30, 2024 and December 31, 2023, there are 300 shares of Series A-1 Convertible Preferred Shares outstanding.

***Series B-1 Convertible Preferred Shares***

The Company has designated 500,000 shares of preferred stock with a par value of \$.001 as “Series B-1 Convertible Preferred Shares”.

The Series B-1 Convertible Preferred Shares entitle their holders to votes equal to the number of shares issuable upon conversion.

Each Series B-1 Convertible Preferred Share is convertible, at the option of the holders, or automatically upon a Qualified Public Offering resulting in gross proceeds to the Company of not less than \$30 million, in whole but no in part, into 6 shares of common stock.

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

The Series B-1 Preferred Shares shall be entitled to receive an annual dividend, payable in newly issued common stock, in an amount equal to ten percent of the number of then existing Series B-1 Preferred Shares issued and outstanding prior and in preference to any declaration or payment of any dividend on the common stock or any other capital stock of the Corporation. This Dividend shall be cumulative.

As of June 30, 2024 and December 31, 2023, there are 5 shares of Series B-1 Convertible Preferred Shares outstanding.

***Common Stock Issuances***

The Company is authorized to issue 975,000,000 shares of common stock with a par value of \$0.001 per share as of June 30, 2024 and December 31, 2023.

***Six months ended June 30, 2024***

During the six months ended June 30, 2024, the Company issued 62,166 shares of common stock for services with a market value of \$270,372 based on the market price of the Company's stock on the grant date.

During the six months ended June 30, 2024, the Company converted \$15,210 of outstanding debt into 2,942 shares of common stock.

During the six months ended June 30, 2024, the Company issued 125,000 shares of common stock for warrant exercises during the six months ended June 30, 2024 for approximately \$250,000.

During the six months ended June 30, 2024, the Company agreed to repurchase 117,359 shares of common stock for \$1.00 that had been previously issued to a service provider. As of the repurchase date, the Company and service provider agreed to release all claims with no restrictions.

***Six months ended June 30, 2023***

During the six months ended June 30, 2023, the Company issued 113,834 shares of common stock for services with a market value of \$404,919 based on the market price of the Company's stock when on the grant date.

During the six months ended June 30, 2023, the Company converted \$252,357 of outstanding debt into 252,357 shares of common stock.

During the six months ended June 30, 2023, The Company issued 249,333 shares of common stock for cash proceeds \$374,000.

During the six months ended June 30, 2023, the Company settled a legal matter by issuing an individual \$81,000 in cash, 200,000 shares of common stock, and 150,000 five-year common stock warrants with an exercise price of \$1.50. The fair value of the shares of common stock and warrants were estimated at \$639,500 based on quoted market prices for the common stock and a Black-Scholes pricing model for the warrants and the following assumptions: expected term of 5 years, risk free interest rate of 3.72% and volatility of 121.00%. The aggregate settlement amount of \$720,500 has been reflected as a component of general and administrative expenses in the three and six months ended June 30, 2023.

In January 2023, the, the Company entered into a share exchange agreement with the noncontrolling interest holder of 10% of the Company's other controlled subsidiary, BSLS whereby the Company exchanged 500,000 shares of common stock for 100 shares of BSLS shares held by the noncontrolling interest.

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

***Common Stock and Warrants for Services***

On April 8, 2024, the Company entered into an agreement with a service provider to provide certain services until December 27, 2025 in exchange for 60,000 shares of common stock with a fair value of \$860,400 based on the market price of the Company's common stock on the grant date which will be recognized as expense and an increase to additional paid in capital over the service term. As of June 30, 2024, \$727,415 of unrecognized stock-based compensation remained to be recognized through December 2025.

Further, the Company issued the service provider a common stock purchase warrant ("Warrant") which permits the service provider to purchase 50,000, 50,000 and 100,000 shares of the Company's common stock at a price of \$4.00 per share, \$5.00 per share and \$6.00 per share, respectively. The Warrant is immediately exercisable at any time, in whole or in part, by the service provider from April 8, 2024, to April 8, 2029. The total estimated grant date fair value of the Warrant using the Black-Scholes option pricing model was \$1,943,500 and will be recognized into expense over the term of the service provider's agreement. The following inputs were utilized in the Black-Scholes option pricing model to estimate the Warrant fair value: common stock price \$10.78, exercise price of \$4 - \$6, volatility of 124.34%, and risk-free rate of 4.43%. The initial value of the warrant has been reflected as an increase to additional paid in capital and prepaid expenses. During the six months ended June 30, 2024, we amortized \$256,864 into expense. As of June 30, 2024, the remaining unrecognized prepaid amount related to this warrant issued for services was \$1,686,636 of which \$1,120,298 has been classified within prepaid expenses and other assets and \$566,338 is classified within long-term other assets on the consolidated balance sheets.

**Note 10 – Commitments and Contingencies**

***Operating Leases***

On March 15, 2024, the Company entered into a thirty-eight (38) month lease for office space commencing April 1, 2024. On April 1, 2024, the Company occupied its new expanded office space in Fort Lauderdale, Florida and received the months of April and May rent free. Monthly lease payments are \$10,159, \$10,329 and \$10,504 for the periods June 1, 2024 through May 31, 2025, June 1, 2025 through May 31, 2026 and June 1, 2026 through May 31, 2027, respectively. Further, the Company executed a lease for office equipment which commenced April 2024 and requires monthly lease payments of \$1,029 through July 2027.

Upon the leases commencing, the Company recognized an operating right-of-use asset and operating lease liabilities of approximately \$340,000 for the present value of the lease payments required over the term of the lease using a weighted average incremental borrowing rate of 12%.

Right-of-use asset is summarized below:

	<b>June 30, 2024</b>	<b>December 31, 2023</b>
Right -of-use assets	\$ 340,401	\$ -
Accumulated amortization	(22,067)	-
Right -of-use assets, net	<u>\$ 318,334</u>	<u>\$ -</u>

Operating lease liabilities are summarized below:

	<b>June 30, 2024</b>	<b>December 31, 2023</b>
Operating lease liabilities, current	\$ 99,567	\$ -
Operating lease liabilities, less current portion	235,598	-
Total operating lease liabilities	<u>\$ 335,165</u>	<u>\$ -</u>

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

Future payments required on the operating lease liabilities, over a weighted average remaining lease term of approximately 3 years, are as follows:

Year Ending	
2024 (remaining)	\$ 67,126
2025	135,444
2026	137,522
2027	59,724
Total	399,816
Less present value discount	(64,651)
Total operating lease liabilities	<u>\$ 335,165</u>

The following table summarizes the supplemental cash flow information for the six month periods ended June 30, 2024 and 2023:

	<u>June 30, 2024</u>	<u>December 31, 2023</u>
Operating cash flows from lease liabilities	<u>\$ 12,217</u>	<u>\$ -</u>

During the three and six months ended June 30, 2024, we incurred rent expense of approximately \$22,000 in connection with the operating leases. During the three and six months ended June 30, 2023, we did not have any leases subject to ASC 842 or leases with a term of less than twelve months.

***Legal Matters***

From time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on the Company's results of operations for that period or future periods.

The Company is a party to an action filed by a former employee in June 2024 alleging a breach of contract to the termination agreement of this employee. Management, in consultation with its attorneys, cannot reasonably estimate a loss associated with this claim, if any, at this time, as the matter is early in the process.

**Note 11 –Income Taxes**

The Company is principally subject to taxation in the United States. The Company has a history of net operating losses both federally and in various states and began utilizing those losses to offset current taxable income in 2024. As net operating loss carryovers become limited or are fully utilized, the Company will accrue current federal and state income tax expense.

The income tax rate for the three and six months ended June 30, 2024 was 26%, and 26%, respectively an increase from the U.S. statutory rate of 21% primarily due to the tax adjustments related to state income taxes, executive compensation, and other nondeductible expenses. The income tax expense for the three and six months ended June 30, 2024 was \$2,313,937 and \$3,498,624, respectively. As of June 30, 2024, included within accounts payable and accrued expenses on the unaudited consolidated balance sheet is income taxes payable of \$3,498,624.

**BioStem Technologies, Inc. and Subsidiaries**  
**Condensed Notes to the Consolidated Financial Statements**  
**For the Six Months Ended June 30, 2024 and 2023**  
**(Unaudited)**

**Note 12 - Subsequent Events**

The Company has evaluated all transactions and events after the balance sheet date through August 28, 2024 the date on which these financials were available to be issued, and except as already included below, has determined that no additional disclosures are required.

The Company issued 50,000 shares of its common stock to three holders of common stock purchase warrants in exchange for a total of approximately \$100,000 in cash.